Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.49 (
reverse transcriptase
)
31,746
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human endogenous retrovirus-H long terminal repeat-associating protein 2
(
HHLA2
) is a newly identified member of B7 family;
HHLA2
protein expression has been suggested to be increased levels in many kinds of human cancers. However,
HHLA2
protein expression in gastric cancer tissues and its clinical significance are still unknown. The purpose of this study was to investigate the
HHLA2
protein expression pattern in gastric cancer tissues and the correlation between
HHLA2
protein expression and clinicopathological characteristics including clinical outcome in gastric cancer patients. In our results, we observed
HHLA2
expression was increased in gastric cancer tissue specimens compared with normal stomach tissue specimens through analyzing
HHLA2
expression data from 408 gastric cancer tissue specimens and 211 normal stomach tissue specimens at databases. Furthermore, we, respectively, performed quantitative
reverse transcriptase
polymerase chain reaction (qRT-PCR) and immunohistochemistry to verify
HHLA2
mRNA and protein expressions in gastric cancer tissues and normal stomach tissues, and found
HHLA2
mRNA and protein expressions were up-regulated in gastric cancer tissues. Moreover, we found high
HHLA2
expression was correlated with advanced clinical stage, deep tumor invasion, lymph node metastasis, distant metastasis and short overall survival in gastric cancer. The multivariable Cox's proportional hazard models indicated high
HHLA2
expression was a poor independent prognostic factor for overall survival in patients with gastric cancer. In conclusion,
HHLA2
protein overexpression in gastric cancer tissue is potential risk factor for malignant status and poor prognosis.
...
PMID:HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer. 3155 67